137 related articles for article (PubMed ID: 12020529)
1. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.
Paton NI; Aboulhab J; Karim F
Lancet; 2002 May; 359(9318):1667-8. PubMed ID: 12020529
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
Paton NI; Aboulhab J
HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
4. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
[No Abstract] [Full Text] [Related]
5. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
7. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
9. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Zala C; Salomón H; Cahn P
Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
[TBL] [Abstract][Full Text] [Related]
10. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
[TBL] [Abstract][Full Text] [Related]
16. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
[TBL] [Abstract][Full Text] [Related]
17. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals.
Biron F; Lucht F; Peyramond D; Fresard A; Vallet T; Nugier F; Grange J; Malley S; Hamedi-Sangsari F; Vila J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):36-40. PubMed ID: 7648282
[TBL] [Abstract][Full Text] [Related]
19. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.
Molina JM; Ferchal F; Rancinan C; Raffi F; Rozenbaum W; Sereni D; Morlat P; Journot V; Decazes JM; Chêne G
J Infect Dis; 2000 Aug; 182(2):599-602. PubMed ID: 10915095
[TBL] [Abstract][Full Text] [Related]
20. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
